In a nutshell: Haematological immune-related adverse events.

The use of immune checkpoint inhibitors (ICIs) have transformed oncological care. In this 'nutshell review', we summarize the most common haematological immune-related adverse events (irAEs) associated with checkpoint inhibitors. We also outline management strategies and address current evidence regarding ICI rechallenge.